BMS-817399   Click here for help

GtoPdb Ligand ID: 9497

Synonyms: compound 29 [PMID: 25101488]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: BMS-817399 is a selective and orally bioavailable CCR1 receptor antagonist [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 89.87
Molecular weight 438.23
XLogP 2.81
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(CC(O)(C)C)NC(C(=O)N1CCC(C(C1)(C)C)(O)c1ccc(cc1)Cl)C(C)C
Isomeric SMILES O=C(CC(O)(C)C)N[C@@H](C(=O)N1CC[C@](C(C1)(C)C)(O)c1ccc(cc1)Cl)C(C)C
InChI InChI=1S/C23H35ClN2O4/c1-15(2)19(25-18(27)13-22(5,6)29)20(28)26-12-11-23(30,21(3,4)14-26)16-7-9-17(24)10-8-16/h7-10,15,19,29-30H,11-14H2,1-6H3,(H,25,27)/t19-,23+/m1/s1
Immunopharmacology Comments
CCR1 is implicated in maintaining the population of inflammatory cells within the synovial tissues and fluid of joints in human RA patients. Functional potency of BMS-817399 in preclinical assessments failed to translate to efficacy in human trial participants with RA.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
BMS-817399 was a clinical candidate for RA that reached Phase 2 clinical trial